70 related articles for article (PubMed ID: 8627572)
1. Characterization of CP-122,721; a nonpeptide antagonist of the neurokinin NK1 receptor.
McLean S; Ganong A; Seymour PA; Bryce DK; Crawford RT; Morrone J; Reynolds LS; Schmidt AW; Zorn S; Watson J; Fossa A; DePasquale M; Rosen T; Nagahisa A; Tsuchiya M; Heym J
J Pharmacol Exp Ther; 1996 May; 277(2):900-8. PubMed ID: 8627572
[TBL] [Abstract][Full Text] [Related]
2. Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptor.
McLean S; Ganong A; Seymour PA; Snider RM; Desai MC; Rosen T; Bryce DK; Longo KP; Reynolds LS; Robinson G
J Pharmacol Exp Ther; 1993 Oct; 267(1):472-9. PubMed ID: 7693914
[TBL] [Abstract][Full Text] [Related]
3. Comparative, general pharmacology of SDZ NKT 343, a novel, selective NK1 receptor antagonist.
Walpole CS; Brown MC; James IF; Campbell EA; McIntyre P; Docherty R; Ko S; Hedley L; Ewan S; Buchheit KH; Urban LA
Br J Pharmacol; 1998 May; 124(1):83-92. PubMed ID: 9630347
[TBL] [Abstract][Full Text] [Related]
4. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]-4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin 1 receptor: II. Neurochemical and behavioral characterization.
Steinberg R; Alonso R; Rouquier L; Desvignes C; Michaud JC; Cudennec A; Jung M; Simiand J; Griebel G; Emonds-Alt X; Le Fur G; Soubrié P
J Pharmacol Exp Ther; 2002 Dec; 303(3):1180-8. PubMed ID: 12438542
[TBL] [Abstract][Full Text] [Related]
5. SSR240600 [(R)-2-(1-[2-[4-[2-[3,5-bis(trifluoromethyl)phenyl]acetyl]-2-(3,4-dichlorophenyl)-2-morpholinyl]ethyl]- 4-piperidinyl)-2-methylpropanamide], a centrally active nonpeptide antagonist of the tachykinin neurokinin-1 receptor: I. biochemical and pharmacological characterization.
Emonds-Alt X; Proietto V; Steinberg R; Oury-Donat F; Vigé X; Vilain P; Naline E; Daoui S; Advenier C; Le Fur G; Maffrand JP; Soubrié P; Pascal M
J Pharmacol Exp Ther; 2002 Dec; 303(3):1171-9. PubMed ID: 12438541
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo characterization of MDL 105,212A, a nonpeptide NK-1/NK-2 tachykinin receptor antagonist.
Kudlacz EM; Shatzer SA; Knippenberg RW; Logan DE; Poirot M; van Giersbergen PL; Burkholder TP
J Pharmacol Exp Ther; 1996 May; 277(2):840-51. PubMed ID: 8627566
[TBL] [Abstract][Full Text] [Related]
7. Involvement of the central tachykinin NK1 receptor during maintenance of mechanical hypersensitivity induced by diabetes in the rat.
Field MJ; McCleary S; Boden P; Suman-Chauhan N; Hughes J; Singh L
J Pharmacol Exp Ther; 1998 Jun; 285(3):1226-32. PubMed ID: 9618426
[TBL] [Abstract][Full Text] [Related]
8. Pharmacological characterization of ZD6021: a novel, orally active antagonist of the tachykinin receptors.
Rumsey WL; Aharony D; Bialecki RA; Abbott BM; Barthlow HG; Caccese R; Ghanekar S; Lengel D; McCarthy M; Wenrich B; Undem B; Ohnmacht C; Shenvi A; Albert JS; Brown F; Bernstein PR; Russell K
J Pharmacol Exp Ther; 2001 Jul; 298(1):307-15. PubMed ID: 11408556
[TBL] [Abstract][Full Text] [Related]
9. A new NK1 receptor antagonist (CP-99,994) prevents the increase in tracheal vascular permeability produced by hypertonic saline.
Piedimonte G; Bertrand C; Geppetti P; Snider RM; Desai MC; Nadel JA
J Pharmacol Exp Ther; 1993 Jul; 266(1):270-3. PubMed ID: 7687291
[TBL] [Abstract][Full Text] [Related]
10. Pharmacological characterization of LY303870: a novel, potent and selective nonpeptide substance P (neurokinin-1) receptor antagonist.
Gitter BD; Bruns RF; Howbert JJ; Waters DC; Threlkeld PG; Cox LM; Nixon JA; Lobb KL; Mason NR; Stengel PW
J Pharmacol Exp Ther; 1995 Nov; 275(2):737-44. PubMed ID: 7473161
[TBL] [Abstract][Full Text] [Related]
11. Differential activation of the epithelial and smooth muscle NK1 receptors by synthetic tachykinin agonists in guinea-pig trachea.
Figini M; Emanueli C; Bertrand C; Sicuteri R; Regoli D; Geppetti P
Br J Pharmacol; 1997 Jun; 121(4):773-81. PubMed ID: 9208147
[TBL] [Abstract][Full Text] [Related]
12. LY303870, a centrally active neurokinin-1 antagonist with a long duration of action.
Iyengar S; Hipskind PA; Gehlert DR; Schober D; Lobb KL; Nixon JA; Helton DR; Kallman MJ; Boucher S; Couture R; Li DL; Simmons RM
J Pharmacol Exp Ther; 1997 Feb; 280(2):774-85. PubMed ID: 9023291
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological profile of (2R-trans)-4-[1-[3,5-bis(trifluoromethyl)benzoyl]-2-(phenylmethyl)-4-piperidinyl]-N-(2,6-dimethylphenyl)-1-acetamide (S)-Hydroxybutanedioate (R116301), an orally and centrally active neurokinin-1 receptor antagonist.
Megens AA; Ashton D; Vermeire JC; Vermote PC; Hens KA; Hillen LC; Fransen JF; Mahieu M; Heylen L; Leysen JE; Jurzak MR; Janssens F
J Pharmacol Exp Ther; 2002 Aug; 302(2):696-709. PubMed ID: 12130734
[TBL] [Abstract][Full Text] [Related]
14. MEN 11420 (Nepadutant), a novel glycosylated bicyclic peptide tachykinin NK2 receptor antagonist.
Catalioto RM; Criscuoli M; Cucchi P; Giachetti A; Gianotti D; Giuliani S; Lecci A; Lippi A; Patacchini R; Quartara L; Renzetti AR; Tramontana M; Arcamone F; Maggi CA
Br J Pharmacol; 1998 Jan; 123(1):81-91. PubMed ID: 9484857
[TBL] [Abstract][Full Text] [Related]
15. Evidence for adrenergic and tachykinin activity in venom of the stonefish (Synanceja trachynis).
Hopkins BJ; Hodgson WC; Sutherland SK
Toxicon; 1996 May; 34(5):541-54. PubMed ID: 8783449
[TBL] [Abstract][Full Text] [Related]
16. Pharmacology of MEN 11467: a potent new selective and orally- effective peptidomimetic tachykinin NK(1) receptor antagonist.
Cirillo R; Astolfi M; Conte B; Lopez G; Parlani M; Sacco G; Terracciano R; Fincham CI; Sisto A; Evangelista S; Maggi CA; Manzini S
Neuropeptides; 2001; 35(3-4):137-47. PubMed ID: 11884203
[TBL] [Abstract][Full Text] [Related]
17. Discovery and stereoselective synthesis of the novel isochroman neurokinin-1 receptor antagonist 'CJ-17,493'.
Shishido Y; Wakabayashi H; Koike H; Ueno N; Nukui S; Yamagishi T; Murata Y; Naganeo F; Mizutani M; Shimada K; Fujiwara Y; Sakakibara A; Suga O; Kusano R; Ueda S; Kanai Y; Tsuchiya M; Satake K
Bioorg Med Chem; 2008 Aug; 16(15):7193-205. PubMed ID: 18640044
[TBL] [Abstract][Full Text] [Related]
18. Neurokinin receptors (NK1, NK2) in the mouse: a pharmacological study.
Nsa Allogho S; Nguyen-Le XK; Gobeil F; Pheng LH; Regoli D
Can J Physiol Pharmacol; 1997 Jun; 75(6):552-7. PubMed ID: 9276127
[TBL] [Abstract][Full Text] [Related]
19. Novel triple neurokinin receptor antagonist CS-003 strongly inhibits neurokinin related responses.
Tsuchida H; Takahashi S; Nosaka E; Mukaiyama O; Yamashita M; Morimoto K
Eur J Pharmacol; 2008 May; 586(1-3):306-12. PubMed ID: 18353309
[TBL] [Abstract][Full Text] [Related]
20. Characterization of receptors mediating contraction induced by tachykinins in the guinea-pig isolated common bile duct.
Patacchini R; Barthó L; Maggi CA
Br J Pharmacol; 1997 Dec; 122(8):1633-8. PubMed ID: 9422808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
